Physician profile
Augustine J Kellis
NPI 1437193828
$1,312.26
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $284 · 2021: $194 · 2022: $113 · 2023: $202 · 2024: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $650.35 | 2019-2024 | Centurion, Hydrus Microstent, Clareon |
| Horizon Therapeutics Plc | $155.71 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $152.69 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $63.53 | 2021-2023 | |
| Allergan, INC. | $62.79 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $40.10 | 2022-2024 | Xiidra |
| Kala Pharmaceuticals, INC. | $32.04 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $31.08 | 2019-2020 | |
| Ocular Therapeutix, INC. | $27.01 | 2024 | Dextenza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Abbvie INC. | $18.64 | 2022 | |
| Merz North America, INC. | $18.22 | 2019 | |
| Oyster Point Pharma, INC. | $16.59 | 2022 | |
| Shire North American Group INC | $12.78 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augustine Kellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.